Perceptions of Women that Prevent Participation in Clinical Trials in the Affluent Versus Impoverished Communities of Miami, Florida

Download Article

DOI: 10.21522/TIJCR.2014.05.02.Art001

Authors : Lois Collie-Acasio


A gender gap exists in biomedical research because more Caucasian men take part than women. As a result, recommended dosages are based on the male physiology with the risks to women unknown. The symptoms, severity, prevalence and age of onset of many diseases may be different in men. Warning signs, and adverse effects may also be different in women and the number of women who have Adverse Events from taking male based recommended dosages is unknown. The gender gap may contribute to medication errors which cause an increasingly large amount of deaths each year. Although women participants are needed and mandated, they may be underrepresented because of child-bearing age and its fluctuating hormones. The possible long-term effect of study drugs on women's gonads is unknown. Women may have a knowledge gap that needs to be bridged as they may not be aware of biomedical medicine research, are unfamiliar with the terms being used to describe the topic, and when faced with multiple therapeutic options, may worry about making informed decisions. Shareholders and women benefit when the gender gap is decreased, safety and efficacy is increased and the result of research become more generalizable. This study investigated perception barriers to participation in Clinical Trials of the women of Liberty City who were 94% African-American, were contrasted with the women of Coral Gables who were 90% Latin-American. This study has never been done before and investigates the barriers that prevent women who are ambulatory patients, from participating in clinical studies.

Keywords: Gender gap, Women’s health research, Barriers to participation.


[1]. Aliyar, C. (2004). Research, Evidence and Recommendations, Michael Littlejohns, Peter (Eds,), Rawlins, (Author) Delivering Quality in the NHS (p.161). Oxon. UK: Radcliffe Medical Press

[2]. Bain, L. J., (2005, July). Crossroads in Clinical Trials. The Journal of the American Society for Experimental Neuro Therapies (NeuroRx), 2(3), 525-528, Retrieved from

[3]. Bill-Axelson, A., Christensson, A., Carlsson, M., Norlén, B. J., & Holmberg, L. (2008). Experiences of Randomization: Interviews with Patients and Clinicians in the SPCG-IV Trial. Scandinavian Journal of Urology & Nephrology, 42(4), 358-363. Retrieved from

[4]. Briggs, L. (2002). Reproducing Empire: Race, Sex, Science, and U.S. Imperialism in Puerto Rico. University of California Press: Berkeley, 2002. Retrieved from

[5]. CDC., (2018). Syphilis Study at Tuskegee, US Public Health Service, Retrieved from

[6]. CDC., (2018). High blood Pressure in the United States. Retrieved from

[7]. CISCRP, (2017). Most important information influencing decision to participate. Center for Information and Study on Clinical Research Participation. Retrieved from

[8]. CISCRP, (2006). Recruitment and Retention, Center for Information and Study on Clinical Research Participation. Retrieved from

[9]. Coakley, M., Fadiran, E. O., Parrish, L. J., Griffith, R. A., Weiss, E., & Carter, C. (2012). Dialogues on Diversifying Clinical Trials: Successful Strategies for Engaging Women and Minorities in Clinical Trials, Journal of Women's Health, 21(7), 713-716. Retrieved from,

[10]. Costenbader, K. H., Brome, D., Blanch, D., Gall, V., Karlson, E., & Liang, M. H. (2007).

[11]. Factors Determining Participation in Prevention Trials Among Systemic Lupus Erythematosus Patients: Qualitative Study. Arthritis & Rheumatism-Arthritis Care & Research, 57(1), 49-55. Retrieved from

[12]. Davis, S, (2003), Recruitment and Retention of Women in Clinical Studies, and the Critical Role of Relevance, A Report of the Task Force sponsored by the NIH Office of Research on Women’s Health, Retrieved from

[13]. Drennan, K. B. (2002). Patient Recruitment: The Costly and Growing Bottleneck in Drug Development. Drug Discovery Today, 7(3), 167-170. Retrieved from

[14]. FDA, (2018) Regulations, Guidance, and Reports related to Women’s Health, Retrieved from

[15]. Getz, K. A. (2008). Public Confidence and Trust Today, A Review of Public Opinion Polls. Monitor. Retrieved from

[16]. HRSA, (2013) Women’s Health USA 2013. Retrieved from

[17]. Jenkinson, C., et al., (2005). Patient Attitudes to Clinical Trials: Development of a Questionnaire and Results from Asthma and Cancer Patients. Health Expectations, 8(3), 244-252.

[18]. Retrieved from, K., Mager, N., (2016) Women’s involvement in clinical trials: historical perspective and future implications, Pharmacy Practice (Granada). 2016 Jan-Mar; 14(1): 708. Retrieved from

[19]. NCI, (2004). What is Randomization? Retrieved from http:// trials/learningabout/what-is-randomization

[20]. NIH, (2012). NIH Policy and Guidelines in the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended, October, 2001. The NIH Revitalization Act of 1993, Retrieved from

[21]. NIH, (2018). What health issues or conditions are specific to women only? Retrieved from

[22]. Schroeder, R, et al., (2018) Sex and Gender Differences in Migraine—Evaluating Knowledge Gaps, Journal of Women's Health Vol. 27, No. 8, Retrieved from: SWHR, (2008). Survey of US Adults on Clinical Trials Research Participation. Society for Women’s Health Research. Retrieved from

[23]. Sood A, et al., (2009). Patients' Attitudes and Preferences About Participation and Recruitment Strategies in Clinical Trials, Mayo Clinic Proc. 2009, 84(3), 243-247.

[24]. Retrieved from and 84_3_243__index.html

[25]. Sperling, B. (2017). Coral Gables, Florida, Research Tools. Retrieved from

[26]. University of Miami Health System. (2008). Liberty City Community Advisory Board. Retrieved from

[27]. US Census. (2012) Retrieved from, S., (2004). Clinical Trials Recruitment and Enrolment: Attitudes, Barriers, and Motivating Factors, A Summary of Literature and Market Research Reports

[28]. National Cancer Institute. Clinical Research Organization, University of Medicine and Dentist of New Jersey. Retrieved from and_enrollment.pdf

[29]. Wittes, J, (2002) Sample Size Calculations for Randomized Controlled Trials, Epidemiologic Reviews, Retrieved from

[30]. Women's Health Initiative Investigators, (2002) Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results.

[31]. Women's Health Initiative Randomized Controlled Trial, Retrieved from

[32]. Worrall, B., (2009). Stroke Risk Factor Profiles in African American Women, An Interim Report from the African-American Anti-Platelet Stroke Prevention Study

[33]. Stroke. 2002 Apr; 33(4): 913–919.Retrieved from

[34]. Wright, J. et al., (2006). Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. The Lancet Oncology, 7(2), 141- 148. Retrieved from 2045(06)70576-9.pdf Available appendices

[35]. Exemption Notification- IRB ID: 2018/02/19

[36]. Letters of Approval by Ethics Committee, Oct.13, 2012

[37]. Introduction and Consent Page for Survey

[38]. and the Survey Questionnaire English and Spanish versions